SaveIN is a healthcare fintech startup based in Gurugram, India, that offers no-cost EMI payment options for outpatient and wellness care to patients and healthcare providers.

This Startup Deep Dive explains what SaveIN does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

SaveIN in Brief

• What it is: SaveIN is an Indian Healthcare no-cost EMI fintech company based in Gurugram.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• SaveIN offers no-cost EMI payment options for outpatient and wellness care such as dental, dermatology, fertility, haircare, hearing, fitness, Ayurveda and homeopathy.
• It reports a network of more than 7,000 healthcare and wellness centres across India (company-stated).
• Its QR code-based checkout works with HDFC Bank, ICICI Bank and IDFC First Bank.
• Funding: Over Rs 100 crore (about $12 million) (reported).

SaveIN Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is SaveIN?

SaveIN operates in the Healthcare no-cost EMI fintech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to SaveIN.

• SaveIN offers no-cost EMI payment options for outpatient and wellness care such as dental, dermatology, fertility, haircare, hearing, fitness, Ayurveda and homeopathy.
• It reports a network of more than 7,000 healthcare and wellness centres across India (company-stated).
• Its QR code-based checkout works with HDFC Bank, ICICI Bank and IDFC First Bank.
• It is developing welUp, a B2B wellness platform for employers.

The Origin Story of SaveIN

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Jitin Bhasin, Anurag Varma, Gaurav Luthra.
• The company is Y Combinator-backed.
• Reports differ on founding: one says 2020 with Jitin Bhasin, Anurag Varma and Gaurav Luthra; another says 2022 by Bhasin alone.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Healthcare no-cost EMI fintech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• April 2022: reported seed funding of about $4 million.
• Seed funding later grew to over $7 million in total (reported).
• April 2025: raised Rs 37 crore (reported).
• Over 5 lakh customer applications processed in three years (company-stated).

SaveIN Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• 2022: seed round led by Pioneer Fund, with Oliver Jung, Grant Park Ventures, Leblon Capital and others (reported).
• Seed extended to a total of Rs 64 crore (about $7.5 million) (reported).
• April 2025: Rs 37 crore led by 10X Founders, Oliver Jung and Leblon Capital, with Stem AI (reported).

How Does SaveIN Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• The company provides no-cost EMI financing to patients at partner healthcare centres, with banks involved in the checkout flow (reported).

The Numbers: SaveIN Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Revenue reportedly rose 250% in FY2025 (company-stated); absolute revenue and loss figures were not found.
• More than 7,000 healthcare and wellness centres in network (company-stated).

Market Opportunity for SaveIN

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Demand drivers: rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings.
• Reach: How much of the market SaveIN can serve depends on its product readiness, distribution and regulatory approvals.

Technology and Product at SaveIN

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Checkout uses a QR code-based system built with partner banks.

Team and Culture at SaveIN

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Jitin Bhasin is founder and CEO.

SaveIN Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of SaveIN vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for SaveIN

• No absolute revenue or loss figures were found in sources read.
• Reports differ on founding year and co-founder list.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

SaveIN Growth Outlook: What to Watch

• New funding is to be used to expand no-cost EMI offerings, grow the healthcare network and develop products including welUp.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether SaveIN can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where SaveIN Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for SaveIN

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for SaveIN.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from SaveIN

Studying a company in the Healthcare no-cost EMI fintech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about SaveIN.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate SaveIN as a Startup

• Customer clarity: Can SaveIN name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

SaveIN is part of India’s growing Healthcare no-cost EMI fintech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

SaveIN FAQs: Frequently Asked Questions

What is SaveIN?

SaveIN is a healthcare fintech startup based in Gurugram, India, that offers no-cost EMI payment options for outpatient and wellness care to patients and healthcare providers. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded SaveIN?

SaveIN was founded by Jitin Bhasin, Anurag Varma, Gaurav Luthra, and the company reports a founding year of reports differ: 2020 or 2022.

How much funding has SaveIN raised?

Over Rs 100 crore (about $12 million) (reported). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does SaveIN make money?

SaveIN earns revenue from its Healthcare no-cost EMI fintech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of SaveIN?

Competitors of SaveIN depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for SaveIN?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Mylab Discovery Solutions — Mylab: revenue went from Rs 8 crore to Rs 825 crore, then fell | MedGenome — MedGenome: India’s genomics player with a $47.5M Series E. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.